Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
about
Challenges in orphan drug development and regulatory policy in China.Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.Application of discrete choice experiments to enhance stakeholder engagement as a strategy for advancing implementation: a systematic review.Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review.Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.
P2860
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Quantifying benefit-risk prefe ...... sease patients and caregivers.
@en
type
label
Quantifying benefit-risk prefe ...... sease patients and caregivers.
@en
prefLabel
Quantifying benefit-risk prefe ...... sease patients and caregivers.
@en
P2860
P50
P1476
Quantifying benefit-risk prefe ...... sease patients and caregivers.
@en
P2093
P2860
P2888
P356
10.1186/S13023-016-0444-9
P577
2016-05-26T00:00:00Z
P6179
1033336451